Published in Genome Res on January 01, 2001
HGVbase: a human sequence variation database emphasizing data quality and a broad spectrum of data sources. Nucleic Acids Res (2002) 4.08
The effect that genotyping errors have on the robustness of common linkage-disequilibrium measures. Am J Hum Genet (2001) 2.29
Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res (2005) 2.11
Single nucleotide polymorphism seeking long term association with complex disease. Nucleic Acids Res (2002) 1.33
Polymorphic segmental duplications at 8p23.1 challenge the determination of individual defensin gene repertoires and the assembly of a contiguous human reference sequence. BMC Genomics (2004) 1.32
Genotyping-by-sequencing (GBS), an ultimate marker-assisted selection (MAS) tool to accelerate plant breeding. Front Plant Sci (2014) 1.26
Genotyping-by-Sequencing in Plants. Biology (Basel) (2012) 1.25
iFRET: an improved fluorescence system for DNA-melting analysis. Genome Res (2002) 1.11
Competitive enzymatic reaction to control allele-specific extensions. Nucleic Acids Res (2005) 1.09
DASH-2: flexible, low-cost, and high-throughput SNP genotyping by dynamic allele-specific hybridization on membrane arrays. Genome Res (2003) 1.06
A survey of ABCA1 sequence variation confirms association with dementia. Hum Mutat (2009) 1.03
Homogeneous point mutation detection by quantum dot-mediated two-color fluorescence coincidence analysis. Nucleic Acids Res (2006) 1.03
Towards compendia of negative genetic association studies: an example for Alzheimer disease. Hum Genet (2005) 1.00
The effect of ABCA1 gene polymorphisms on ischaemic stroke risk and relationship with lipid profile. BMC Med Genet (2007) 0.96
Variability in the kinesin light chain 1 gene may influence risk of age-related cataract. Mol Vis (2007) 0.92
Isothermal discrimination of single-nucleotide polymorphisms via real-time kinetic desorption and label-free detection of DNA using silicon photonic microring resonator arrays. Anal Chem (2011) 0.92
Variants of CYP46A1 may interact with age and APOE to influence CSF Abeta42 levels in Alzheimer's disease. Hum Genet (2004) 0.92
Genomic DNA methylation changes in response to folic acid supplementation in a population-based intervention study among women of reproductive age. PLoS One (2011) 0.90
Paraoxonase gene polymorphisms and haplotype analysis in a stroke population. BMC Med Genet (2006) 0.90
Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease. Hum Genet (2004) 0.87
Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease. Neurogenetics (2004) 0.85
Comprehensive genetic evaluation of common E-cadherin sequence variants and prostate cancer risk: strong confirmation of functional promoter SNP. Hum Genet (2005) 0.85
Pleiotropy in the presence of allelic heterogeneity: alternative genetic models for the influence of APOE on serum LDL, CSF amyloid-β42, and dementia. J Alzheimers Dis (2010) 0.85
DNA diagnostics by surface-bound melt-curve reactions. J Mol Diagn (2007) 0.84
A Novel SNPs Detection Method Based on Gold Magnetic Nanoparticles Array and Single Base Extension. Theranostics (2012) 0.84
Rapid detection of single nucleotide polymorphisms associated with spinal muscular atrophy by use of a reusable fibre-optic biosensor. Nucleic Acids Res (2004) 0.83
Efficient SNP Discovery by Combining Microarray and Lab-on-a-Chip Data for Animal Breeding and Selection. Microarrays (Basel) (2015) 0.83
Straightforward detection of SNPs in double-stranded DNA by using exonuclease III/nuclease S1/PNA system. Nucleic Acids Res (2004) 0.83
Neuropathologic assessment of dementia markers in identical and fraternal twins. Brain Pathol (2014) 0.81
Ubiquitin carboxy-terminal hydrolase L1 (UCHL1) S18Y polymorphism in Alzheimer's disease. Mol Neurodegener (2010) 0.81
Variability in the CIITA gene interacts with HLA in multiple sclerosis. Genes Immun (2014) 0.80
CYP17 gene polymorphism in relation to breast cancer risk: a case-control study. Breast Cancer Res (2005) 0.78
Parkinson's disease in relation to pesticide exposure and nuclear encoded mitochondrial complex I gene variants. J Biomed Biotechnol (2006) 0.77
Ubiquitin carboxyl-terminal esterase L1 (UCHL1) S18Y polymorphism in patients with cataracts. Ophthalmic Genet (2011) 0.77
Genotyping by alkaline dehybridization using graphically encoded particles. Chemistry (2011) 0.76
BACE1 gene variants do not influence BACE1 activity, levels of APP or Aβ isoforms in CSF in Alzheimer's disease. Mol Neurodegener (2010) 0.76
A unified view of polymer, dumbbell, and oligonucleotide DNA nearest-neighbor thermodynamics. Proc Natl Acad Sci U S A (1998) 24.28
Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet (1999) 24.24
Large-scale identification, mapping, and genotyping of single-nucleotide polymorphisms in the human genome. Science (1998) 18.23
HGBASE: a database of SNPs and other variations in and around human genes. Nucleic Acids Res (2000) 11.75
Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem (1997) 7.72
dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Res (2000) 6.84
The essence of SNPs. Gene (1999) 6.44
Relaxation kinetics of dimer formation by self complementary oligonucleotides. J Mol Biol (1971) 4.77
Mining SNPs from EST databases. Genome Res (1999) 4.31
Stability and properties of double and triple helices: dramatic effects of RNA or DNA backbone composition. Science (1992) 3.53
Sequence diversity in 36 candidate genes for cardiovascular disorders. Am J Hum Genet (1999) 3.02
Dynamic allele-specific hybridization. A new method for scoring single nucleotide polymorphisms. Nat Biotechnol (1999) 2.75
Population variation of human mtDNA control region sequences detected by enzymatic amplification and sequence-specific oligonucleotide probes. Am J Hum Genet (1991) 2.56
Overlapping genomic sequences: a treasure trove of single-nucleotide polymorphisms. Genome Res (1998) 2.24
Theory of thermal transitions in low molecular weight RNA chains. J Mol Biol (1968) 2.19
Drug firms to create public database of genetic mutations. Science (1999) 2.14
Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res (1982) 2.01
Detection of point mutations in human genes by the solid-phase minisequencing method. Clin Chim Acta (1994) 1.23
No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm (Vienna) (2000) 1.09
Multiplex genotype determination at a DNA sequence polymorphism cluster in the human immunoglobulin heavy-chain region. Genomics (1995) 1.07
Identification of 167 polymorphisms in 88 genes from candidate neurodegeneration pathways. Gene (1999) 0.89
Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med (2004) 16.58
Controlled silver-staining of nucleolus organizer regions with a protective colloidal developer: a 1-step method. Experientia (1980) 13.12
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology (2009) 5.94
HGVbase: a human sequence variation database emphasizing data quality and a broad spectrum of data sources. Nucleic Acids Res (2002) 4.08
Development of bioinformatics resources for display and analysis of copy number and other structural variants in the human genome. Cytogenet Genome Res (2006) 3.68
Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol (1999) 3.62
Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol (2001) 3.19
CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology (2003) 3.18
SNP association studies in Alzheimer's disease highlight problems for complex disease analysis. Trends Genet (2001) 2.86
Dynamic allele-specific hybridization. A new method for scoring single nucleotide polymorphisms. Nat Biotechnol (1999) 2.75
Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology (1999) 2.74
Splinkerettes--improved vectorettes for greater efficiency in PCR walking. Nucleic Acids Res (1995) 2.51
Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett (2000) 2.25
Is adult-onset coeliac disease due to a low-grade lymphoma of intraepithelial T lymphocytes? Lancet (1991) 2.21
Imaging and CSF studies in the preclinical diagnosis of Alzheimer's disease. Ann N Y Acad Sci (2007) 2.11
Presenilin-I, presenilin-II, and VLDL-R associations in early onset Alzheimer's disease. Lancet (1997) 2.06
Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett (2001) 2.05
HGVbase: a curated resource describing human DNA variation and phenotype relationships. Nucleic Acids Res (2004) 1.93
Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci Lett (2001) 1.89
Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem (2001) 1.87
CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol Scand (2007) 1.85
Cerebrospinal fluid tau protein as a biochemical marker for Alzheimer's disease: a community based follow up study. J Neurol Neurosurg Psychiatry (1998) 1.83
Gamma-secretase-dependent amyloid-beta is increased in Niemann-Pick type C: a cross-sectional study. Neurology (2010) 1.78
Standardization of measurement of beta-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid (2000) 1.75
CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology (2005) 1.73
Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia. J Clin Immunol (1999) 1.68
ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol (1999) 1.68
Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds. Dement Geriatr Cogn Disord (2003) 1.67
A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease. Ann Clin Biochem (2009) 1.66
An imprinted gene(s) for diabetes? Nat Genet (1995) 1.65
Cerebrospinal fluid biomarkers of white matter lesions - cross-sectional results from the LADIS study. Eur J Neurol (2009) 1.64
Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology (2011) 1.63
Intrathecal inflammation precedes development of Alzheimer's disease. J Neurol Neurosurg Psychiatry (2003) 1.62
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
New evidence for an association between the CSF HVA:5-HIAA ratio and psychopathic traits. J Neurol Neurosurg Psychiatry (2003) 1.58
Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry (2004) 1.53
A population study on blood-brain barrier function in 85-year-olds: relation to Alzheimer's disease and vascular dementia. Neurology (1998) 1.50
Recommendations for locus-specific databases and their curation. Hum Mutat (2008) 1.49
Differential staining of the satellite regions of human acrocentric chromosomes. Experientia (1975) 1.49
Altered blood-brain-barrier function in Alzheimer's disease? Acta Neurol Scand (1994) 1.44
Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology (2007) 1.43
Cerebrospinal fluid monoamine metabolites and atmospheric pressure. Biol Psychiatry (1996) 1.39
Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport (1999) 1.38
Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology (2006) 1.37
APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology (2004) 1.33
Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett (1999) 1.32
Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res (2005) 1.32
Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology (2012) 1.31
Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis. Genes Immun (2005) 1.28
Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet (2004) 1.26
Both total and phosphorylated tau are increased in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 1.26
Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol (1998) 1.21
CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neural Transm (Vienna) (2000) 1.20
Evidence for an important role of perilipin in the regulation of human adipocyte lipolysis. Diabetologia (2003) 1.20
Increased serum-GFAP in patients with severe traumatic brain injury is related to outcome. J Neurol Sci (2005) 1.20
Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. J Neurosci Res (2001) 1.19
Neurochemical dissection of synaptic pathology in Alzheimer's disease. Int Psychogeriatr (1998) 1.18
CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology (2010) 1.18
Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease. Neurobiol Aging (2007) 1.17
Improving data and knowledge management to better integrate health care and research. J Intern Med (2013) 1.15
Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J Alzheimers Dis (2000) 1.13
CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival. Dement Geriatr Cogn Disord (2006) 1.13
Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. Acta Neurochir (Wien) (2008) 1.12
CSF studies in violent offenders. I. 5-HIAA as a negative and HVA as a positive predictor of psychopathy. J Neural Transm (Vienna) (2001) 1.11
Genetic linkage analysis of collagen-induced arthritis in the mouse. Eur J Immunol (1998) 1.11
Neurofilament protein levels in CSF are increased in dementia. Neurology (1999) 1.11
Treatment of Alzheimer's disease with clioquinol. Dement Geriatr Cogn Disord (2001) 1.10
Local and systemic GM-CSF increase in Alzheimer's disease and vascular dementia. Acta Neurol Scand (2001) 1.10
Point mutations (Thr240Arg and Gln311Stop) [correction of Thr240Arg and Ala311Stop] in the Parkin gene. Biochem Biophys Res Commun (1998) 1.09
No association between the alpha2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression. J Neural Transm (Vienna) (2000) 1.09
Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample. Neurology (1999) 1.09
Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol (2007) 1.08
Chromosome core structure revealed by silver staining. Chromosoma (1979) 1.08
Cytoskeleton proteins in CSF distinguish frontotemporal dementia from AD. Neurology (2000) 1.07
Harmonized diagnostic criteria for Alzheimer's disease: recommendations. J Intern Med (2014) 1.07
A rapid technique for producing silver-stained nucleolus organizer regions and trypsin-giemsa bands on human chromosomes. Hum Genet (1978) 1.06
Symptoms, vascular risk factors and blood-brain barrier function in relation to CT white-matter changes in dementia. Eur Neurol (2000) 1.06
Blood brain barrier function in vascular dementia. Acta Neurol Scand (1990) 1.06
Inflammatory markers in matched plasma and cerebrospinal fluid from patients with Alzheimer's disease. Dement Geriatr Cogn Disord (2003) 1.05
Increased intrathecal inflammatory activity in frontotemporal dementia: pathophysiological implications. J Neurol Neurosurg Psychiatry (2004) 1.04
Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. Cancer Res (2001) 1.04
Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study. Dement Geriatr Cogn Disord (2010) 1.04
Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem Res (2000) 1.03
The genetics of primary nocturnal enuresis: inheritance and suggestion of a second major gene on chromosome 12q. J Med Genet (1997) 1.03
A population study of apoE genotype at the age of 85: relation to dementia, cerebrovascular disease, and mortality. J Neurol Neurosurg Psychiatry (1998) 1.02
Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neurosci Lett (2001) 1.01
HLA genetics and allergic disease. Thorax (1995) 1.00
Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology (2007) 0.99
Karyotypic analysis and evidence of tetraploidy in the North American paddlefish, Polyodon spathula. Science (1976) 0.99
Evaluation of CSF biomarkers for axonal and neuronal degeneration, gliosis, and beta-amyloid metabolism in Alzheimer's disease. J Neurol Neurosurg Psychiatry (2001) 0.99
Identification of androstenedione in a river containing paper mill effluent. Environ Toxicol Chem (2001) 0.99
Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. Eur J Hum Genet (2001) 0.98